While much attention has been paid to ‘traditional’ biomarkers, research into digital biomarkers for neurodegenerative diseases is rapidly growing. Because the cognitive and motor changes preceding clinically-measurable manifestations of neurodegenerative diseases are subtle, there is interest in leveraging technologies that could easily be or already embedded in individuals’ daily lives – such as smartphones, smartwatches, and tablets – to collect behavioral and physiological data. If validated, digital biomarkers may facilitate early detection, prediction of health-related outcomes, and longitudinal monitoring, but they also come with ethical challenges.
Funding: National Institute on Aging: P30-AG-073105
Publications:
Claire Erickson & Emily A. Largent, Monitoring (on) Your Mind – Digital Biomarkers for Alzheimer’s Disease, in Digital Health Care Outside of Traditional Clinical Settings: Ethical, Legal and Regulatory Challenges and Opportunities, 92-104 (I.G. Cohen, C. Shachar, D. Kramer, J. Adler-Milstein eds., 2024).
Erickson CM, Wexler A, Largent EA. Digital Biomarkers for Neurodegenerative Disease. JAMA Neurol. 2025 Jan 1;82(1):5-6. doi: 10.1001/jamaneurol.2024.3533. PMID: 39432291; PMCID: PMC11729353.
Erickson CM, Wexler A, Largent EA. Alzheimer’s in the modern age: Ethical challenges in the use of digital monitoring to identify cognitive changes. Inform Health Soc Care. 2024 Jan 2;49(1):1-13. doi: 10.1080/17538157.2023.2294203. PMID: 38116960; PMCID: PMC11001527.